Conflicts of interest
Stroke, Muscular Dystrophy, Arthritis, Musculoskeletal, Myasthenia Gravis, Neurological Disorders
RARE DISEASE, MUSCULAR DYSTROPHY, STROKE, ARTHRITIS, SKIN DISEASES, MYASTHENIA GRAVIS, DISEASE, NEUROLOGICAL DISORDERS
Tuan Vu is the USF Site Principal Investigator for MG clinical trials sponsored by Alexion, AstraZeneca Rare Disease, argenx, Ra/UCB Pharma, Horizon/Viela Bio, Janssen/Momenta, Sanofi, Regeneron, and Cartesian Therapeutics; he receives speaker and consultant honoraria from Alexion, AstraZeneca Rare Disease, UCB, and argenx. Stephan Ortiz, Kathleen N Beasley, and Rasha Aguzzi are employees of Alexion, AstraZeneca Rare Disease and own stock in AstraZeneca. Masahisa Katsuno has received speaker honoraria from Biogen Japan, Chugai, and Eisai, and financial research support from Alexion, AstraZeneca Rare Disease, argenx, Eisai, and Mitsubishi-Tanabe. Djillali Annane has received consultancy fees from Alexion, AstraZeneca Rare Disease. Renato Mantegazza serves on advisory boards for Alexion, AstraZeneca Rare Disease, UCB, argenx, Catalyst, and Sanofi. He has received speaker’s honoraria from Alexion, AstraZeneca Rare Disease, UCB, and argenx, and consultancy fees from Catalyst. James F Howard Jr has received research support (paid to his institution) from argenx, Cartesian Therapeutics, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, Ra Pharmaceuticals (now UCB), and Takeda Pharmaceuticals; honoraria from Alexion, AstraZeneca Rare Disease, argenx, Immunovant Inc., Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi US, and Viela Bio Inc. (now Horizon Therapeutics); and non-financial support from Alexion, AstraZeneca Rare Disease, argenx, Ra Pharmaceuticals (now UCB), and Toleranzia AB.